Loading...
NPI 1629028733 · Little Rock, AR · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Kent Zocchi is a ophthalmology physician provider located in Little Rock, Arkansas. This profile covers 21 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Kent Zocchi |
| Address | 9800 Lile Dr |
| City | Little Rock |
| State | AR |
| ZIP | 72205 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | May 11, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.8M |
| Medicaid | $32.8K |
Practice profile and tenure: KENT ZOCCHI is an Ophthalmology Physician in LITTLE ROCK, AR with an NPI enumerated on 2006-05-11 (~20 years ago), indicating long-standing Medicare/Medicaid participation and likely established referral relationships and patient panel development over roughly two decades. The specialty and longevity align with a sustained outpatient procedural practice rather than a recently established or transient billing profile.
Medicare scale and payer mix: This provider’s Medicare lifetime revenue is $1.8M versus $32.8K in Medicaid, indicating Medicare overwhelmingly dominates the revenue stream and that the provider operates as effectively Medicare-centric in scale. Medicaid billing exists but is immaterial relative to Medicare, so analyses of business risk or growth should center on Medicare reimbursement and utilization trends.
Service-line concentration: The top Medicare revenue drivers are intravitreal drug codes and an isolated intravitreal injection code — J0178 (aflibercept), J2777 (faricimab-svoa), and 67028 — consistent with a retina-focused medical ophthalmology practice that delivers frequent anti-VEGF and related intravitreal therapies. Complementary high-volume diagnostic imaging (92134) and E/M visits support a clinic workflow centered on retinal disease management, monitoring, and repeat injections.
Revenue concentration risk: The provider’s top three Medicare codes account for 77.4% of total Medicare revenue, and the top three Medicaid codes account for 98.4% of total Medicaid revenue, indicating heavy reliance on a small set of injection and retinal imaging services for almost all payer revenue. That concentration makes overall revenue sensitive to changes in drug utilization, payer coverage policies, or reimbursement for these specific codes.
Medicare competitive standing — injections and imaging: On Medicare, J0178 generates $930.1K (50.9% of Medicare revenue) and ranks #941 of 3204 providers nationally (71st percentile; typical, unremarkable volume for this code), while J2777 produces $353.2K (19.3%) and ranks #871 of 2039 (57th percentile; typical). The isolated injection code 67028 accounts for $130.6K (7.1%) and ranks #658 of 4255 (85th percentile; typical), showing solid but not dominant national positioning for core injection procedures.
Medicare outliers in imaging and E/M: Two non-drug codes are statistical outliers on Medicare: 92134 (OCT retinal imaging) accounts for $63.8K and ranks #688 of 26868 providers nationally (97th percentile; extreme outlier, far above typical national volume for this code), and 99213 (established E/M) accounts for $83K and ranks #2631 of 457151 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). These extreme-percentile positions imply the practice sustains unusually high retinal imaging and frequent established-patient visits relative to national peers, consistent with ongoing injection management.
Medicaid volume and in-state standing: Medicaid billing is small in absolute dollars but mirrors the Medicare service mix: 92134 ($17.5K, 53.1%), 92012 ($8.2K, 24.9%), and 67028 ($6.7K, 20.4%) together drive 98.4% of Medicaid revenue. In-state ranks are middling for imaging and exams (92134 ranks #14 of 43, 69th percentile; 92012 ranks #25 of 95, 74th percentile) and low for 67028 (rank #14 of 17, 19th percentile), indicating the provider is a typical to above-typical supplier of retinal imaging and exams in Arkansas but not a dominant statewide injector on Medicaid.
Implications for network and contracting: Given the practice’s concentration in anti-VEGF drugs and retinal imaging, payers and care managers should treat this provider as a retina-centric outpatient service with predictable, recurring treatment episodes. Contracting or utilization management discussions should focus on drug mix and imaging/E/M utilization patterns (notably the extreme outlier status of 92134 and 99213 on Medicare) rather than broad ophthalmology service lines.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
21 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,350 | $690 | $930.1K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 12,180 | $30 | $353.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,630 | $80 | $130.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,410 | $60 | $83K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 430 | $160 | $67.9K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,450 | $30 | $63.8K |
| J2778 | Injection, ranibizumab, 0.1 mg | 330 | $180 | $59.6K |
| J9035 | Injection, bevacizumab, 10 mg | 820 | $60 | $45K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 200 | $110 | $20.9K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 170 | $70 | $11.6K |
Showing 1–10 of 21
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 21 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
21 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 8 | 30 | 390 | $690 | $538.3K |
| J2777 | 10 | 20 | 12,180 | $30 | $504.5K |
| J2778 | 6 | 20 | 270 | $180 | $85K |
| 67028 | 8 | 40 | 270 | $80 | $51.1K |
| J7312 | 2 | 10 | 190 | $160 | $42.6K |
| 67210 | 3 | 10 | 20 | $370 | $28.2K |
| J9035 | 3 | 10 | 410 | $50 | $22.1K |
| 92014 | 165 | 370 | 150 | $70 | $19.1K |
| 99214 | 2,487 | 4,300 | 130 | $70 | $18.8K |
| 67108 | 3 | 10 | 10 | $790 | $10.3K |
Showing 1–10 of 21
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 670 | $30 | $17.5K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 330 | $30 | $8.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 80 | $90 | $6.7K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 20 | $30 | $510 |
| J7999 | Compounded drug, not otherwise classified | 10 | $1 | $30 |
How this provider's Medicaid billing volume and revenue compare to other Arkansas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Arkansas median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 14 | 20 | 260 | $110 | $91.6K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,637 | 1,740 | 550 | $30 | $88.8K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 14 | 40 | 260 | $20 | $26.2K |
| 92012 | For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any… | 25 | 100 | 120 | $30 | $14.3K |
| J7999 | Compounded drug, not otherwise classified | 8 | 10 | 150 | $1 | $420 |
Other providers in the same ZIP code as Kent Zocchi, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.